Vitamin K Study for Thinking and Memory in Coronary Heart Disease
Tests vitamin K against a placebo in adults over 60 with coronary heart disease.
Plain-language title generated from the registry record
Registry title: Vitamin K and Cognition in Coronary Heart Disease (NutriCog)
Key facts
- Where
- Montreal, CanadaSee the site
Where in Canada
- Montreal Heart InstituteMontreal, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Montreal Heart Institute
- Trial code
- NCT06855953
- Record updated
- 4 March 2025
- Original description
The purpose of this pilot study is to obtain a preliminary assessment of the effect of VK supplementation on cognitive performance and vascular function in adults with stable Coronary Heart Disease (CHD)Read full original descriptionShow less
Vitamin K Supplementation to Improve Cognition of Patients With Coronary Heart Disease: a Randomized Controlled Pilot Study
The purpose of this pilot study is to obtain a preliminary assessment of the effect of VK supplementation on cognitive performance and vascular function in adults with stable Coronary Heart Disease (CHD)
Inclusion: Men and women; Age 60 years and older; Medically documented stable Coronary Heart Disease (CHD); Daily dietary intakes of phylloquinone <150 mcg; Non-consumption of vitamin K supplements (i.e. K1 or K2, singly or in combination with other nutrients), or other cognitive aids; Good French or English understanding; Physical exercise not exceeding 2.5 hours/week of moderate to vigorous aerobic activity; Capacity and willingness to sign informed consent.
Exclusion: Recent modification of medication (<2 weeks); Recent acute coronary syndrome (<3 months) or recent coronary revascularization (bypass surgery or percutaneous coronary intervention, <3 months); Cognitive impairment (based on telephone version of the Mini-Mental State Examination test, score <19/23); Malabsorption disorder (advanced liver disease, Crohn's disease); Known left ventricular dysfunction (LVEF < 40%) or chronic heart failure; Warfarin (Coumadin) use; Diagnosis of depression or uncontrolled anxiety; Patient with auditory or vision impairments not properly corrected by glasses or hearing aids; Unable to read the informed consent form or unable to understand the oral explanations provided by the assessor.